Michelle Lycke1, Lies Pottel1, Hans Pottel2, Lore Ketelaars3, Karin Stellamans4, Koen Van Eygen1,5, Philippe Vergauwe6, Patrick Werbrouck7, Laurence Goethals4, Patricia Schofield8, Tom Boterberg9, Philip R Debruyne1,8. 1. Division of Medical Oncology, Cancer Centre, General Hospital Groeninge, Kortrijk, Belgium. 2. Department of Public Health and Primary Care @ Kulak, Catholic University Leuven Kulak, Kortrijk, Belgium. 3. Department of Neuropsychology, General Hospital Groeninge, Kortrijk, Belgium. 4. Division of Radiotherapy, Cancer Centre, General Hospital Groeninge, Kortrijk, Belgium. 5. Division of Haematology, Cancer Centre, General Hospital Groeninge, Kortrijk, Belgium. 6. Department of Gastro-Enterology, General Hospital Groeninge, Kortrijk, Belgium. 7. Department of Urology, General Hospital Groeninge, Kortrijk, Belgium. 8. Faculty of Health, Social Care and Education, Anglia Ruskin University, Chelmsford, UK. 9. Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
Abstract
INTRODUCTION: Recent research in the field of cancer-related cognitive impairments (CRCI) has shown CRCI presentation prior to treatment initiation. Some have attributed these problems to worry and fatigue, whereas others have suggested an influence of age, IQ, and other psychosocial and medical factors. METHODS: Patients (≥18 years) with a histologically confirmed diagnosis of a solid cancer or hematological malignancy, scheduled for a curative treatment, were evaluated with a baseline neuropsychological assessment including Patient-Reported Outcome Measures (PROMs). PROMs entailed distress, anxiety and depression, fatigue, and cognitive complaints. The neuropsychological assessment comprised several cognitive domains such as premorbid IQ, attention, processing speed, flexibility, verbal and visual episodic memory, and verbal fluency. RESULTS: Cross-sectional data of 125 patients were collected. Patients had a mean age of 60.9 years (range: 30.0-85.0) and comprised primarily females (65.6%). Patients presented with cancer of following sites: breast (44.0%), digestive (28.8%), urological (11.2%), gynecologic (8.0%), hematologic malignancy (4.8%), and lung (3.2%). Patients presented with a premorbid IQ of 105.3 (range: 79.0-124.0). In 29.6% of patients, a CRCI was detected. Binary logistic regression analyses showed that a lower premorbid IQ (β = -.084, P < .01) and a higher level of fatigue (β = -.054, P < .05) predicted baseline CRCI. Premorbid IQ also predicted performance on individual cognitive domains. Some domains were also influenced by age, gender, having a breast cancer diagnosis, and an active treatment for hypertension. CONCLUSION: Premorbid IQ and fatigue are important predictors of baseline CRCI. Therefore, we advise researchers to implement a short IQ test when conducting clinical trials on CRCI.
INTRODUCTION: Recent research in the field of cancer-related cognitive impairments (CRCI) has shown CRCI presentation prior to treatment initiation. Some have attributed these problems to worry and fatigue, whereas others have suggested an influence of age, IQ, and other psychosocial and medical factors. METHODS:Patients (≥18 years) with a histologically confirmed diagnosis of a solid cancer or hematological malignancy, scheduled for a curative treatment, were evaluated with a baseline neuropsychological assessment including Patient-Reported Outcome Measures (PROMs). PROMs entailed distress, anxiety and depression, fatigue, and cognitive complaints. The neuropsychological assessment comprised several cognitive domains such as premorbid IQ, attention, processing speed, flexibility, verbal and visual episodic memory, and verbal fluency. RESULTS: Cross-sectional data of 125 patients were collected. Patients had a mean age of 60.9 years (range: 30.0-85.0) and comprised primarily females (65.6%). Patients presented with cancer of following sites: breast (44.0%), digestive (28.8%), urological (11.2%), gynecologic (8.0%), hematologic malignancy (4.8%), and lung (3.2%). Patients presented with a premorbid IQ of 105.3 (range: 79.0-124.0). In 29.6% of patients, a CRCI was detected. Binary logistic regression analyses showed that a lower premorbid IQ (β = -.084, P < .01) and a higher level of fatigue (β = -.054, P < .05) predicted baseline CRCI. Premorbid IQ also predicted performance on individual cognitive domains. Some domains were also influenced by age, gender, having a breast cancer diagnosis, and an active treatment for hypertension. CONCLUSION: Premorbid IQ and fatigue are important predictors of baseline CRCI. Therefore, we advise researchers to implement a short IQ test when conducting clinical trials on CRCI.
Authors: Natalie G Regier; Aanand D Naik; Elizabeth A Mulligan; Ziad S Nasreddine; Jane A Driver; Yvonne H-F Sada; Jennifer Moye Journal: Psychooncology Date: 2019-06-13 Impact factor: 3.894
Authors: Zev M Nakamura; Allison M Deal; Donald L Rosenstein; Laura J Quillen; Stephanie A Chien; William A Wood; Thomas C Shea; Eliza M Park Journal: Support Care Cancer Date: 2020-08-23 Impact factor: 3.603
Authors: Parul Sinha; Alex W K Wong; Dorina Kallogjeri; Jay F Piccirillo Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-11-01 Impact factor: 6.223